VRDN

Viridian Therapeutics, Inc.\de

A biotechnology company developing new treatments for thyroid eye disease, a rare autoimmune condition that makes the tissues behind the eye swell and bulge. Its lead experimental medicine, veligrotug, is an antibody designed to block the protein driving that swelling. The company was formed under its current name in 2022, taking "Viridian" from the green pigment, a nod to fresh growth.

Recent Activity

Show $

2025Q4

1 sell

Maverick CapitalEXIT

-2.21M shares

Maverick CapitalEXIT

-2.21M shares

2025Q3

1 sell

Maverick CapitalTRIM

-44.3K shares(-2.0%)

Maverick CapitalTRIM

-44.3K shares(-2.0%)

2025Q2

1 buy

Maverick CapitalADD

+195.7K shares(+9.5%)

Maverick CapitalADD

+195.7K shares(+9.5%)

2025Q1

1 buy

Maverick CapitalADD

+7.4K shares(+0.4%)

Maverick CapitalADD

+7.4K shares(+0.4%)

Loading more activity...